It’s Show Time Klone 4.0 is simmering on the horizon
September 2nd，2020 Press Release
"Made in Changping" Young Students Training Camp Visited Great Bay Bio
[2020/9/2, Dongguan]At 9am, September 8th EST, Michael Chen, CEO of Great Bay Bio will present on the Medivest Conference, unveiling our Klone 4.0 platform.
Great Bay Bio is an innovative, AI-bioproduction technology company poised to disrupt the biological drug development industry by means of its AI-enabled multi-platform. The company will also seek to engage a "blue ocean" approach to apply its machine learning technologies to CAR-T, molecular diagnostics, mAb sequencing, and further laboratory-based applications. Great Bay Bio aims to work with world-class institutions, drug innovators and industry collaborators as it prepares for the commercial launch of its cell line and cell culture media applications, Klone4.0 and AlfaMedX, this fall.
Klone4.0 uses AI algorithms, supercomputer processors and robotic cell selectors that can be placed on site, has demonstrated a unique ability to reduce cell line development time by as much as 80%. By eliminating many of the pain points involved in cell selection, it can quickly identify high expressing cells and thereby produce a higher quality cell line. Similarly, AlfaMedX shortens the cell media formulation process by 80% and provides drug innovators with the added benefits of control and confidentiality of their own cell culture media.
About Great Bay Bio
Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.
GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.
GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.
The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.
For more details, please visit：www.greatbay-bio.com
Contact for business：firstname.lastname@example.org
Contact for media and investment: email@example.com